Amytrx Therapeutics Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Later Stage VC
- (In Progress)
- Latest Deal Amount
-
$28M
- Investors
-
2
Amytrx Therapeutics General Information
Description
Developer of anti-inflammatory peptide medicines intended to treat inflammation and metabolic disorders. company's medicines use cell-penetrating decoy peptides that selectively target leukocyte cells and AMTX-100 reversibly binds to the importin Alpha5, beta1 complex used by large, proinflammatory transcription factors to transport them into the cell's nucleus and binds to DNA or genes that then produce chemokines, cytokines and growth factors, enabling patients to get treatment for inflammation and metabolic syndromes safely.
Contact Information
Website
www.amytrx.comCorporate Office
- 40 Burton Hills Boulevard
- Suite 260
- Nashville, TN 37215
- United States
Corporate Office
- 40 Burton Hills Boulevard
- Suite 260
- Nashville, TN 37215
- United States
Amytrx Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | $28M | In Progress | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC | 31-Jan-2024 | Completed | Clinical Trials - Phase 2 | |||
| 2. Later Stage VC (Series A) | 20-Sep-2020 | $18M | $18.6M | Completed | Clinical Trials - Phase 2 | |
| 1. Early Stage VC (Series A) | 01-Jul-2016 | $600K | $600K | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Amytrx Therapeutics Comparisons
Industry
Financing
Details
Amytrx Therapeutics Competitors (4)
One of Amytrx Therapeutics’s 4 competitors is Alnylam Pharmaceuticals, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Novo Nordisk | Corporation | Bagsvaerd, Denmark | ||||
| Eli Lilly | Corporation | Indianapolis, IN | ||||
| Novartis | Corporation | Basel, Switzerland |
Amytrx Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Amytrx Therapeutics Patents
Amytrx Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4522119-A2 | Formulations comprising short peptides and uses in the treatment of inflammatory or autoimmune diseases | Pending | 12-May-2022 | ||
| CA-3230157-A1 | Leukocyte-specific cell penetrating molecules | Pending | 23-Aug-2021 | ||
| EP-4392051-A1 | Leukocyte-specific cell penetrating molecules | Pending | 23-Aug-2021 | C07K7/08 |
Amytrx Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Amytrx Therapeutics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Burch Investment Group | Venture Capital | Minority | ||
| Rugosa Partners | Venture Capital | Minority |
Amytrx Therapeutics FAQs
-
When was Amytrx Therapeutics founded?
Amytrx Therapeutics was founded in 2014.
-
Where is Amytrx Therapeutics headquartered?
Amytrx Therapeutics is headquartered in Nashville, TN.
-
What is the size of Amytrx Therapeutics?
Amytrx Therapeutics has 4 total employees.
-
What industry is Amytrx Therapeutics in?
Amytrx Therapeutics’s primary industry is Drug Discovery.
-
Is Amytrx Therapeutics a private or public company?
Amytrx Therapeutics is a Private company.
-
What is Amytrx Therapeutics’s current revenue?
The current revenue for Amytrx Therapeutics is .
-
How much funding has Amytrx Therapeutics raised over time?
Amytrx Therapeutics has raised $49.6M.
-
Who are Amytrx Therapeutics’s investors?
Burch Investment Group and Rugosa Partners have invested in Amytrx Therapeutics.
-
Who are Amytrx Therapeutics’s competitors?
Alnylam Pharmaceuticals, Novo Nordisk, Eli Lilly, and Novartis are competitors of Amytrx Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
